Inhalon Biopharma, Inc.
Publicly observedMorrisville, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Morrisville | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Inhalon Biopharma, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | HFQSJ2GMNRU6 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Sept 2025Publicly observed
NIH SBIR/STTR award: Development of IN-003PI as passive immunization against human metapneumovirus infection
USD 1,013,468.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2025Publicly observed
NIH SBIR/STTR award: IND-enabling development for IN-005, an inhaled muco-trapping mAb therapy against Influenza A
USD 1,013,003.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant21 Jun 2024Publicly observed
NIH SBIR/STTR award: Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV
USD 1,024,945.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant15 May 2024Publicly observed
NIH SBIR/STTR award: IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection
USD 1,024,879.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Mar 2024Publicly observed
NIH SBIR/STTR award: SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections
USD 1,023,875.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jun 2023Publicly observed
NIH SBIR/STTR award: GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus
USD 608,832.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.